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Both locally and globally, Human Papillomavirus (HPV) affects millions of people every 
year not discriminating based on gender, socioeconomic status, age, or health history. Persistent 
HPV infection has been linked to cancers of the mouth/throat, penis, anus, rectum, and most 
famously cervical cancer. The utilization and application of Human Papillomavirus (HPV) 
vaccines are drastically reducing the prevalence of HPV in vaccine recipients. A severe lack of 
HPV and HPV vaccine education are limiting the protective ability of these vaccines. Becoming 
available only as recently as 2006 there is a lack of HPV education, longitudinal research on 
long-term efficacy, and moral dilemmas among parents that negatively effect vaccine uptake. 
The purpose of this manuscript is to educate about HPV, HPV mechanisms of action, 
demographic information, and the consequences of HPV infection by presenting credible 
evidence. Next, there will be an examination of the current research on HPV vaccinations, the 
controversies surrounding them, and the current recommendations for HPV protection. Seeing 
reductions in HPV and its consequences will help guide Oklahoma, the US, and the world to 
enact HPV vaccination policies that decrease HPV infection prevalence and thereby increase the 
health of the population.  
HPV Infection and Cervical Cancer 
First, a detailed knowledge of Human Papillomavirus is crucial to understanding HPV 
vaccination. HPV is the most common sexually transmitted infection and there are over 100 
HPV genotypes, which are identified numerically by their discovery [1]. HPV infection is 
transmitted from person to person during vaginal, anal, or oral sex. Typically, symptoms do not 
develop with HPV infection making it easy to spread because individuals may not know they are 
infected. If symptoms do arise they typically manifest themselves as genital warts. Most HPV 
infections are cleared within 2 years, some are sooner and some are longer. Frequent Pap smears 
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are a good way to monitor current infection and watch for signs of persistent infection or tissue 
abnormalities [2]. Those with autoimmune disorders, such as human immunodeficiency virus 
(HIV) that lower the body’s ability to fight disease, injuries, or who are currently fighting disease 
may be unable to overcome the infection alone. However, the immunosuppressed are not the 
only population who may be unable to clear HPV infection. Similar to the contracting the flu or 
another infection, people who are tired, stressed, as well as those who are not getting adequate 
nutrition are also all at a higher risk of not clearing the infection.  
Even when HPV is cleared a person who is sexually active is at risk for contracting HPV 
again. Additionally, HPV may be dormant for years or recede into periods of latency and return 
more problematic and deft to the immune system. Both reinfection and latent infection can cause 
persistent HPV infection, which has been shown to be the cause of 98% of cervical cancer cases, 
the fourth most frequent cancer in women [3]. Knowing that 98% of cervical cancer cases and 
deaths are attributed to HPV, it is possible to greatly decrease the current 530,000 annual new 
cases of cervical cancer worldwide, of which 270,000 deaths were estimated in 2012 alone [3]. 
Based on this information there is potential for an effective vaccine to drastically decrease 
infection prevalence and transmission.  
HPV is a double stranded DNA virus from the Papillomaviridae family of DNA viruses, 
which are distinguished from other families of viruses because of their control over gene 
expression allowing the virus to take control of the cell’s synthetic machinery[4]. Additionally, 
DNA viruses in this family take control of a cell’s nucleus and have the ability to remain latent 
or dormant for extended amounts of time. HPV virus is packaged in a protein capsid that totals 
8000 base pairs in length [1]. Mechanistically, the virus infects by attaching to the basal 
keratinocytes of the cervical epithelium in females or the penile or anal epithelium in men 
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through existing micro-abrasions in the layer. At this point a healthy immune system would 
typically recognize pro-inflammatory cytokines such as IL-12, IL-18, IFN-γ, and IL-6 produced 
by macrophages that were activated by the invaded epithelial cells [4].  
However, in persistent infection the viral genome becomes merged to the host genome, a 
process called homologous recombination, which causes an overexpression of viral E6 and E7 
genes [5]. Homologous recombination is a process that releases nucleases, which induce double-
stranded DNA breaks, and then repairs the break with the invading virus DNA[6]. The cell 
begins to replicate viral DNA as if it were the original cell’s DNA utilizing the cells already 
present machinery. HPV replication begins with initiating transcription of the viral E6 genes that 
damage and deregulate p53 genes, tumor-suppressor genes, which function to maintain a proper 
cell cycle including growth, division, and death of cells[7]. Without this regulation, mutated cells 
do not undergo apoptosis and mutated DNA begins to collect, eventually causing dysplasia of the 
cervical epithelium [8]. The other protein that is overexpressed in persistent HPV infection is E7, 
which degrades Retinoblastoma protein; a protein responsible for regulating the S-phase of cell 
replication. Disruption of the checkpoints before the S-phase result in increased and unregulated 
cell replication [8]. 
HPV Vaccines on The Market 
This unrestricted cell proliferation leads to tissue dysplasia and neoplasia, which is the 
abnormal cytology indicating cancer. The HPV genotypes are numbered in order of discovery, 
but are categorized by oncogenic potential. Genotypes 16 and 18 are the most cancer causing of 
all the known HPV genotypes. HPV 16 is responsible for approximately 50% of all cervical 
cancer cases and HPV 18 is attributed 15-20% of all cases [1]. The first HPV vaccine, bivalent 
Cervarix (2vHPV), was designed to protect from these two HPV genotypes specifically. Since its 
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introduction however, several more HPV genotypes have been classified as high-risk or 
oncogenic. HPV 16, 18, 31, 33, 34, 39, 45, 51, 52, 56, 58, 59, and 66 are the currently known 
high-risk HPV genotypes. The more recent quadrivalent vaccine, Gardasil (4vHPV) provides 
protection from genotypes 16, 18, 6, and 11. Most recently, Gardasil 9 (9vHPV) protects from 
these four genotypes and 31, 33, 45, 52, and 58 additionally [9]. These vaccines are aimed at 
avoiding the predecessor of cervical cancer, cervical intraepithelial neoplasia (CIN), which is 
graded from 1 to 3 (most severe). CIN1 lesions are typically cleared by a healthy immune 
system, but if they proceed to CIN2/3 it is estimated that 30 to 50% will ultimately progress to 
invasive cervical cancer[8].  However, with the use of a HPV vaccine, the aforementioned CIN1 
lesions rarely develop into mature cervical cancer because the antibodies produced in response to 
the vaccine prevent the virus from binding to the epithelium and causing infection [4]. 
HPV Vaccines 
Knowing what HPV is and how it operates, HPV vaccines are aimed at creating B-
memory cells before a person’s exposure to HPV to prevent persistent infection. All three of the 
current HPV vaccines on the market are of the same type and utilize the same mechanisms to 
generate an immune response. HPV vaccines are protein subunit vaccines, which present an 
antigen, a protein used to induce an immune response, to the immune system to promote the 
activation of the immune system and the formation of memory cells [10]. Subunit vaccines do 
not contain any live vaccine therefore they are extremely safe and there is absolutely no risk of 
contracting the disease from the vaccine. However, because there is no live portion of the virus 
in the vaccine, vaccine manufactures must take extra care to analyze and select the subunits of 
the pathogen that contain the antigenic properties to present to the immune system. There is also 
less certainty that the vaccine will create enough memory and plasma cells from B-cells with the 
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ability to produce antibodies to ward off future infection. For this reason the vaccine is given in 
either two or three doses several months apart [10].   
The virus-like proteins (VLP) that mimic HPV genotypes are grown in yeast cells by 
combining genetic material from the virus. Next, the VLPs are removed from yeast cells and 
purified, combined with a catalyst and purification buffer [11]. The catalyst that the VLPs are 
combined with is called an adjuvant; a substance that enhances and controls the magnitude of the 
immune response [7]. There are only a handful of adjuvants and alum, an aluminum salt-based 
adjuvant (aluminum hydroxyphosphate sulfate), is the substance added to HPV vaccines to 
increase the immune response [11]. Alum signals myeloid differentiation primary response gene 
88 (MyD88) and TIR-domain-containing adapter-inducing interferon-beta (TRIF). Both MyD88 
and TRIF activate Toll-like receptors (TLRs), beginning the signal cascade that produces 
proinflammatory cytokines and chemokines as well as recruiting immune cells [12]. A more 
detailed explanation of the mechanisms that produce these cytokines and immunity follows.  
Vaccine Mechanism 
Picture yourself as a small molecule of HPV virus-like protein that is about to be 
intramuscularly injected into a HPV vaccine recipient. Epithelial cells, T-cells, B-cells, and many 
other cells in response to the vaccine entering the body produce Proinflammatory cytokines such 
as IL-12, IL-18, and IFN-γ. As the vaccine enters the body, immature dendritic cells surrounding 
the injection site take it up. Inside these cells, the protein-adjuvant combination is processed 
through the endosomal pathway and is broken down in the phagolysosome and bound to major 
histocompatibility complex type II (MHC II) molecules forming a MHC II: protein-adjuvant 
complex [13].  
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The MHC II: protein-adjuvant complex returns to the dendritic cell surface as the 
activated cell proceeds along the lymph channel and runs into immature T helper 2 cells (TH2). 
This TH2 cell is activated when the MHC II complex binds with the TH2 receptor; the TH2 cell 
begins rapid proliferation[13]. As all of this was happening, MHC II: protein-adjuvant 
complexes were encountering B-cells in the lymph node and binding. Now the TH2 cells and B-
cells meet, this meeting is referred to as linked recognition. The B-cells are activated and become 
either memory cells or plasma cells, which are able to produce antibodies capable of 
remembering the antigen the next time it enters the body [13]. The plasma cells will continue 
secreting antibodies for up to two weeks after vaccination and B-memory cells will be stored in 
lymphoid tissues including the spleen, lymph nodes, and Peyer’s patches [13].  
The next time the virus enters the body the B-memory cells will begin rapidly replicating 
and producing plasma cells to secrete specific antibodies targeting the virus.  This mechanism, 
called T-dependent, is how protein subunit vaccines confer immunity from a virus without giving 
a live and possibly contractible virus within a vaccine. These vaccines use only specific antigens 
from the virus to produce a memorable immune response and memory cells. The use of multiple 
doses, 2 or 3 in the case of HPV vaccination, is intended to present the antigens to the system 
adequately enough to confer lifetime HPV prevention.  
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The visual below is a simplified version of this type of vaccine mechanism.  
 
Figure 1 a. HPV vaccine (with vaccine-like proteins) is intramuscularly injected. b. Immature dendritic cells around the injection 
site take up the vaccine. c. The protein-adjuvant combination is broken down in the phagolysosome of the endosomal pathway 
and is bound to the Major Histocompatibility Complex (MHC II) forming a MHCII: protein-adjuvant complex (d.) e. MHCII: 
protein-adjuvant complex binds to TH2 cells in the lymph channel and B-cells in the lymph nodes, activating the TH2 cells. f. 
TH2 cells and B-cells bind, referred to as linked recognition. B-cells are activated. g. Activated B-cells begin rapidly producing 
memory cells or plasma cells. After the creation of memory B-cells and plasma cells the memory cells are stored in lymphoid 
tissues and are poised to begin rapid plasma cells production if the virus reenters the body. Plasma cells will produce specific 
antibodies able to combat the virus [13]. 
HPV Vaccine Efficacy 
Efficacy of a new vaccine is crucial for the vaccine to initially make it out of the lab, into 
production, and finally implemented into mandatory vaccination lists. All three of the HPV 
vaccines, 2vHPV, 4vHPV, and 9vHPV, are effective at reducing the incidence of persistent HPV 
infection, genital warts, anal, rectal, mouth/throat, penile, and cervical cancer in men and 
women. Within 6 years of the Gardasil (4vHPV) vaccine introduction (2006) there was an 89% 
reduction in the prevalence of HPV 6/11/16/18 infection in females’ ages 14-24 in comparison to 
unvaccinated females [9]. At the same time there was also a reduction of infection prevalence in 
unvaccinated females in the vaccine era compared to the prevaccine era of 17-49%. This 
provides evidence to support the idea that herd immunity, a high enough percentage of the 
population being vaccinated, protects unvaccinated members by default [9].  
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The first country to provide free quadrivalent HPV vaccinations (Gardasil) and try to 
fully implement HPV vaccination was Australia in 2007. Therefore, much of the efficacy data 
that researchers and consumers rely on comes out of Australia and other high vaccine utilization 
countries such as Finland and Sweden. Data showed that 3 years after vaccine introduction, the 
number of high grade cervical abnormalities (CIN1, 2, 3) was half of what it was pre-vaccine [8]. 
5 years after introduction, low-grade cervical abnormalities were reduced by 34% and high-grade 
abnormalities by 47% in females age 12-26 in comparison to unvaccinated females from a cohort 
study done at introduction of the vaccine[9]. 
 NHANES data collected during the vaccine era (2009-2012) compared to the pre-
vaccine era (pre-2009) showed that HPV infections of types 6/11/16/18 decreased 64% in 
females aged 14-19 years and 34% in females aged 20-24 years [14]. This shows how effective 
HPV vaccination is in preventing persistent HPV infection and thereby preventing cervical 
cancer.  It also provides further evidence that receiving the vaccine earlier (ages 9-13) provides 
more protection than receiving it later (ages 14-26). However, the vaccine has shown 
considerable protection as long as it is received prior to a person becoming sexually active or 
being infected [14].   
The 9vHPV Vaccine 
The most recent HPV vaccine, 9vHPV, was approved by the Food and Drug 
Administration in December 2014 and promises to offer greater protection by covering 9 HPV 
strains as opposed to Gardasil’s 4 strains [15]. Clinical studies compared 9vHPV efficacy against 
4vHPV by recruiting girls’ ages 9-15, women ages 16-26, and men ages 16-26 who were 
negative for HPV at baseline and were seeking HPV vaccination. 7 months after vaccination, 
immunological responses are assessed by comparing geometric mean titers (GMT) of antibodies 
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produced based on which vaccination they received [15]. As previously thought, those 
vaccinated with the 9vHPV vaccine produced antibodies for HPV types 31,33,45,52, and 58 
which are not protected by the 4vHPV vaccine. The immune response for the four shared HPV 
types, 6,11,16, and 18 were virtually identical so there is no loss of coverage with the addition of 
more strains [15].  
Researchers have also stated that a two-dose schedule (6-12 months apart) of 9vHPV 
produced higher GMT levels than the traditional three-dose schedule (0, 2, and 6 months 
between) and therefore is recommended for boys and girls ages 9-14 [15]. Currently, the most 
common HPV vaccination is the 4vHPV Gardasil, but because the 9vHPV vaccine provides 
protection over 5 additional HPV strains the 9vHPV may replace the 4vHPV in utilization in the 
near future. HPV types 6/11/16/18 (those included in 4vHPV) account for nearly 70% of all 
cervical cancer cases, but the extra five strains of HPV covered in the 9vHPV vaccine would 
account for an additional 14.7% of cervical cancer cases. Increasing the vaccines ability to 
prevent up to 84.7% of all persistent HPV-caused cervical cancer cases. 9vHPV would also raise 
overall coverage of vaginal cancer 18.3%, penile cancer 8.2%, and oropharyngeal cancer 
5.7%[15]. Below is a chart showing the efficacy and risk reduction of 9vHPV compared to 
4vHPV [15]. 
 
 
 
 
 
Figure 2 Efficacy of 9vHPV Vaccine [4] 
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The recommended dosage of two of the HPV vaccines, 2vHPV and 4vHPV is 3 times 
with predetermined breaks in between and twice with predetermined breaks for 9vHPV. The 
American College of Obstetricians and Gynecologists (ACOG) recommends 1 – 2 months 
between the first and second dose then 6 months between the second and third doses. However, 
recommendations also stipulate that completion of the vaccine series is more important than 
having the exact time recommendations [16]. To date, long-term trials have not shown a 
significant difference as long as the doses were completed.  
Recommendations 
The recommended age of administration is crucial in HPV vaccination. The vaccine is 
designed to prevent HPV infection, not to treat HPV. For this reason, it is highly recommended 
that males and females be vaccinated before the onset of sexual activity. For this reason, 
recommendations are meant to be before onset of sexual activity. ACOG and the CDC 
recommend vaccination for males and females at age 11-12 [12, 13]. There are catch up 
vaccinations available for male sup to age 21 and females up to age 26 [13]. World Health 
Organization recommends a two-dose schedule with 6 months in between of one of the three 
types of vaccines to females younger than 15 years of age. For females 15-26 they recommend 
the typical 3-dose schedule. A three-dose schedule is also recommended for all persons who may 
be immunocompromised or HIV positive [17]. Immunocompromised individuals, including 
those with HIV, are at an increased likelihood of having persistent HPV infection because of 
their reduced immune system capability and possible inability to receive vaccinations.  
Cervarix (2vHPV) and Gardasil (4vHPV), the first HPV vaccine, were recommended by 
the CDC for the vaccination of females ages 11-12 beginning in 2006. With the HPV 
vaccination’s ability to decrease cervical cancer risk it was only marketed to females until 2009 
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when the CDC began recommending the vaccination to males in addition to females ages 11-12 
[18]. The first barrier for parents deciding whether to vaccinate their sons is lack of knowledge 
of HPV and the HPV vaccine. Primarily, parents perceived HPV as a female disease because of 
its strong link to cervical cancer. However, persistent HPV infection can cause cancers of the 
anus, rectum, mouth/throat, and penis. Adapted Pap tests that check anal, rectal, penile, and 
mouth/throat cytology can identify cancerous cells [19]. However, these tests are not routine and 
are not currently included in the standard of care.  
This is relevant to men because 11,000 men in the United States develop these cancers 
annually as a result of HPV [20]. Many parents overlooked the fact that even if the HPV vaccine 
only prevented cervical cancer, vaccinating men would reduce the number of persistent HPV 
cases in women dramatically because men can be carriers of the disease without ever having 
problems. Vaccinating the entire at-risk population provides widespread coverage for all, 
including those immunocompromised or unable to get the vaccination for medical reasons. This 
widespread coverage will lower infection prevalence as well as transmission thereby decreasing 
the number of HPV-associated cancer cases.  
Concerns preventing high uptake of HPV Vaccine 
There are multiple concerns of parents that prevent them from vaccinating their children 
against HPV. To begin, many adults claim HPV is a “teen disease” and will not be contracted 
after adolescence. However, HPV can be contracted from sexual activity with an infected 
individual at any age. Therefore, over 50% of the population will contract HPV at some point in 
their lifetime [13]. Appropriate HPV vaccination prevents persistent HPV infection up to 99% 
across the lifetime [21]. In a Swedish school-based study, researchers gaged parent’s opinions on 
HPV vaccination in boys as well as girls. Many parents voiced that having boys go unvaccinated 
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places all the sexual and reproductive health responsibility on females, much like many 
traditional ideas surrounding birth control [22]. During the interviews parents expressed that 
equal vaccination of boys and girls would help eliminate this traditional view of sexual and 
reproductive responsibility. Other pro-male vaccination parents shared that they were more 
hesitant vaccinating their daughters without vaccinating their sons. They had fears that perhaps 
the vaccination was not safe for everyone and this made them hesitant to vaccinate in the first 
place. If vaccination was universally recommended they would be more apt to vaccinate both 
children at the same time [22].  
Based on the confusion and concerns surrounding male HPV vaccination the CDC has 
provided many resources to better educate parents on vaccinations for males and females and 
research has been done to quantify the immune responses in men after receiving the HPV 
vaccine [20]. Men show an immune response of nearly 100% sero-conversion to VLP vaccines, 
which is a huge increase from their traditional antibody response of 20-30% from natural HPV 
infection [21]. The potential to protect men from multiple cancers and at the same time protect 
women from persistent HPV that can lead to cervical cancer is substantial and men should 
continue to follow the recommended HPV vaccination schedule. 
In addition to the benefit that HPV vaccines are preventative and should be administered 
at a young age before sexual activity, it has also been shown that earlier administration, ages 11-
13, of the vaccine resulted in higher antibody titers [16].  Multiple studies have shown that age of 
vaccine administration has an effect on antibody production. As age of vaccination increases past 
the recommended 11 – 12 years old the amount of antibodies created, measured as the geometric 
mean titer (GMT), decreases significantly and has been shown to not be effective after 
approximately 26 years of age [23]. A study conducted in 2013 comparing 2 and 3-dose GMTs 
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of females aged 9 – 13 years with 3-dose GMTs of females aged 16 – 26 at months 7, 18, 24,and 
36 showed that the 16 – 26 year old group only ever gained about half or less of the antibodies 
that the 9 – 13 year old [23]. Other researchers have noted that the older the age of vaccination, 
the lower the numbers of HPV-18 B memory cells are generated [24].  
Barriers to Access 
With these recommendations in mind there are still significant barriers for people to 
receive the HPV vaccination. A major barrier is that currently the HPV vaccine is, at current 
prices, a $450 out-of-pocket expense for the series [25]. This cost is a major obstacle for many 
parents looking to vaccinate their children as well as young adults who are interested in the 
catch-up vaccine. Insurance providers vary on their coverage of the HPV vaccination. Some 
completely cover the vaccine cost while others do not consider it a required vaccination and will 
cover a portion, or in some cases, none at all.  
Fortunately, because of HPV vaccines’ immediate impact, safety, and efficacy, it has 
been included as a vaccine being covered under the federally-funded program called Vaccines 
for Children (VFC) [26]. This program provides free vaccination from 16 diseases to protect 
infants, young children, and adolescents up to age 19. Children are eligible for VFC if they are 
Medicaid-eligible, uninsured, underinsured, American Indian, or Alaska native. These vaccines 
are bought at discount by the CDC and distributed to state health departments, public health 
agencies, and other VFC providers where people can go in and receive the vaccination[26]. 
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Table 1 Vaccine-Preventable Diseases Covered under Vaccines For Children (VFC) 
Hepatitis A 
(HepA) 
Hepatitis B 
(HepB) 
Diphtheria 
(DTaP) 
Tetanus 
(DTaP) 
Pertussis 
(DTaP) 
Polio (IPV) 
Rotavirus 
(RV) 
Influenza 
(Flu) 
Chickenpox 
(Varicella) 
Pneumococcal 
(PCV) 
Haemophilus 
influenza 
type b (Hib) 
Meningococcal 
(MenACWY, 
MenB) 
Measles 
(MMR) 
Mumps 
(MMR) 
Rubella 
(MMR) 
Human 
papillomavirus 
(HPV) 
  
[26] 
Despite the high cost, the HPV vaccine is most certainly a cost-effective life-saving 
measure when compared to the cost of cervical cancer treatments. Importantly, the HPV vaccine 
is the only cancer vaccine in current use [27] and, like a lot of other preventable care, needs to be 
made more accessible and affordable. To those in the legislature who are opposed to more 
vaccine accessibility it should be discussed that high vaccine uptake protects the entire 
community through herd immunity and begins to eradicate diseases.  Obstacles surrounding 
vaccination prevent more people from being vaccinated each year. Low vaccine uptake has 
raised questions of whether school requirement of HPV vaccination would increase vaccine 
utilization. Vaccinations rates are highest for vaccines required to enter the public school system 
– MMR (Measles, Mumps and Rubella), Varicella (chicken pox), Polio, TDaP (Tetanus, 
Diphtheria, and Pertussis), and Hepatitis B [26]. If HPV were required for entrance into the 
public school system many fewer parents would question having their children immunized.  
Herd Immunity 
Vaccines like MMR, Varicella, TDaP, and Polio as well as the HPV vaccines protect the 
recipient of the vaccine, but they also protect everyone else. High rates of immunity create “herd 
immunity”; a type of immunity afforded even to those who are unable to be vaccinated because 
of medical reasons [27]. The level of immunity is so high that the disease cannot survive and the 
population benefits by eradicating diseases such as polio, which at one time affected 16,000 
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people a year and none presently [28]. However, when vaccination rates drop below the required 
percentage of the population, say 96% for measles, there begin to be outbreaks of these diseases. 
In December of 2014, there was a measles outbreak in Disney Land that produced 147 positive 
cases for measles spanning across 15 states that could all be traced back to Disney Land during a 
certain time. Researchers estimated that the vaccination rate at that time was somewhere between 
50-86%, well below the recommended 96% [28]. Not vaccinating children puts all children at 
risk to contract very preventable diseases. In 2010 the CDC estimated that nearly 40% of parents 
have delayed or skipped a child’s vaccination [16]. By enforcing HPV vaccination for school the 
number of vaccine recipients would increase dramatically and immunocompromised individuals 
would benefit from the herd immunity as well.   
Political Policy on Vaccinations 
The responsibility to create and enforce vaccine policy is dependent on state government, 
not federal. Each state is responsible for passing laws to enforce vaccinations for school children. 
State legislatures are also responsible for deciding what types of exemptions they will accept 
including and or limited to: medical, philosophical, religious, and personal exemptions. All states 
currently allow medical exemptions, but following the Disney Land measles outbreak the state of 
California signed a bill into law that abolished the personal exemptions for child vaccinations 
and saw increases in vaccine compliance [16]. In Oklahoma, under Oklahoma Statute 70, section 
1210.192 medical, religious, and personal exemptions are allowed. There are fees associated 
with these vaccinations, but they are still available to anyone who wants to opt out. Additionally, 
Oklahoma does not require vaccine education during the exemption process [29].   
In 2015, Senator Ervin Yen from Oklahoma City filed Senate Bill 830 (SB 830) that 
would remove personal and religious exemptions from the current state laws. As of February 
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2016, SB 830 did not make it out of committee and therefore will not be made into law. [29]. 
This bill and others like it would not immediately require the HPV vaccine for all school 
children, but would prevent personal exemptions from the existing required vaccines and would 
move Oklahoma closer to the 42 states and territories that have introduced legislation concerning 
the administration and requiring of the HPV vaccination. Of these, Virginia, Washington D.C., 
and Rhode Island are currently the only territories where the HPV vaccine is required for school 
[30]. These states are leading in the battle against HPV and cervical cancer and will benefit from 
the preventative care for a lifetime. Fear of the safety of the HPV vaccine is not the only reason 
parents want vaccination exemptions.  
Other issues keeping people from vaccinating include a distrust of government control 
and the idea that providing a vaccine for what is a sexually transmitted disease sends the message 
to adolescents that risky sexual behavior is okay. Distrust of government control is not a new 
concern. People are opposed to federal control over medical treatment and believe that it would 
be abused and the government would dictate people’s medical treatment and exemptions would 
no longer be discussed on a case-to-case basis[28]. Senator Yen, who is also a physician, is 
typically a “small government republican”, but urges that not requiring vaccinations had led to a 
public health and safety issue. It is no longer something that can be handled locally, but needs to 
be addressed at the national level and needs to be enforced before the small outbreaks of 
measles, mumps, etc. get larger and begin to kill people[7].  
The second concern about HPV vaccination is a moral dilemma: do adolescents result in 
more risky sexual behavior earlier if they are vaccinated against a sexually transmitted disease. 
Opponents of HPV vaccine requirements claim that HPV vaccination should not be required for 
public school because it cannot be caught in the classroom via cough, sneeze, touch etc. and 
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because a student cannot contract the disease except through sexual activity therefore it shouldn’t 
be required to attend school [27]. As mentioned earlier, the HPV vaccination prevents persistent 
HPV infection, which is present in 98% of cervical cancer cases and leads to at least 250,000 
deaths worldwide every year [3]. If a person never initiates sexual activity then theoretically they 
have no need for the HPV vaccine, but statistics show that over half of sexually-active people 
will contract HPV at some point and it is impossible to know who will clear the virus by 
themselves from those that would benefit from the vaccine [30]. Additionally, the national Youth 
Risk Behavior Survey (YRBS) surveyed 9th - 12th graders from 1991 – 2013 and over 50% report 
already being sexually-active [31]. When discussing HPV transmission, “sexually active” is 
defined as participating in oral, anal, or vaginal sex as well as anytime a person’s genitals comes 
into contact with another person. HPV is too serious of a health concern and too easily prevented 
to put off discussing and accepting adolescent sexual activity. 
Demographics of those receiving HPV Vaccination 
There are multiple non-moral reasons that prevent people from vaccinating themselves or 
their kids. Financial barriers to access were mentioned earlier and frequently do keep people in 
low to middle class from vaccinating. $450/series out of pocket is a very hefty price for a 
vaccination that is not absolutely mandatory yet. Many low-income families can receive the 
vaccination through the Vaccines for Children (VFC) program, but slightly higher income 
families may not have this option available. Other barriers to access include job loss, health 
insurance loss, single parents, multiple jobs, lack of transportation, and lack of healthcare facility 
near them [32]. Lack of knowledge and possible language barriers round out the list as potential 
barriers that prevent parents from being able to vaccinate their children properly [32]. A survey 
by the National Network for Immunization Information revealed that many parents wanted more 
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information before they would be willing to vaccinate at all, which shows that a lack of 
knowledge is a true barrier to vaccine implementation [32].  
Previous studies have shown that the demographic of those who participate in HPV 
vaccinations in the US corresponds with higher socioeconomic status. High socioeconomic 
families were more likely to participate in vaccinations and at the recommended times. 
Additionally, high-income families are more likely to participate in age-appropriate cancer 
screenings, which provides early detection of problems if they do occur. However, statistics also 
demonstrate that families below the poverty line have slightly higher levels of HPV vaccine 
coverage compared to their slightly above the poverty line counterparts because of the multiple 
resources allowing them to get free vaccinations.  
From an ethnic/racial standpoint, Hispanics currently have the highest vaccine coverage 
(47%) followed by African-Americans (39%), Caucasians (38%), then Asian/Pacific Islanders 
(36%) [33]. American Indians are up to 3 times more likely to have persistent HPV than other 
Americans even though they are offered free HPV vaccinations under the Vaccines for Children 
program [34]. This sharp increase is thought to be from a lack of knowledge of HPV vaccination 
protection.  The CDC also released that HPV-associated cervical cancer is higher in African-
American and Hispanic women than in white and non-Hispanic women. However, African-
American and Hispanic men and women had lower rates of HPV-associated oropharyngeal 
cancers than their white and non-Hispanic counterparts [35]. These HPV-associated cancers 
affect more than a million people globally each year and nearly all of these cancers could be 
avoided by having the complete series of HPV vaccinations.  
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US HPV Vaccine Coverage 
Current HPV vaccine coverage in the United States is approximately 63% in females and 
50% in males [36]. Oklahoma, regretfully, only has approximately 39% of females vaccinated 
and 50% of males vaccinated [36]. These statistics include everyone who has received at least 
one dose, but not the recommended series of two or three doses. These vaccine rates are far too 
low to provide adequate population protection from HPV and HPV-associated cancers. To 
achieve herd immunity protection for non-cancerous vaccine-preventable diseases the threshold 
needs to be somewhere between 75-95% depending on the method of transmission and level of 
contagiousness [37]. There has never been a vaccine to prevent cancer so the specific percentage 
required for herd immunity is unknown, but is thought to need to be comparable to non-
cancerous disease percentages. To compare, these are the average vaccine percentages of 
multiple other vaccines: DTap (84.2%), Polio (93.3%), MMR (91.5%), Hepatitis B (91.6%), and 
Varicella (91.0%) [36]. These high vaccine compliance rates still show signs that they may be 
too low to achieve herd immunity, protecting the entire population. Based on that alone 
researchers are pushing for greater HPV vaccination to hopefully begin eliminating total HPV 
cases.   
The U.S. government has started making HPV vaccination a priority as well. The Office 
of Disease Prevention and Health Promotion is in charge of making goals to improve the health 
of the nation. The current set of goals are called Healthy People 2020 and were initiated in 2010 
[38]. By 2020 they would like to see complete series HPV vaccination of 80% of females and 
males. In 2012 the office found the percentages to be 28.1 % and 6.9% for females and males. A 
60% increase in vaccine coverage is a very high goal, but it shows that they believe HPV 
vaccination is an effective means of disease prevention [38]. Other Healthy People 2020 
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immunization information says that proper immunization reduces direct health care costs by $9.9 
billion and saves $33.4 billion in indirect costs. Increases in life expectancy and decreases in the 
spread of infectious disease are always associated with higher vaccine coverage [38].  
Knowing the positive impact increased HPV vaccination would have on the United 
States; there are a few ways to increase vaccine compliance. HPV vaccine uptake would increase 
most dramatically if the series of vaccinations were required for entry into public schools. This 
would cover a wider margin of individuals and if it were mandatory for both girls and boys the 
results would be very dramatic. If HPV vaccines were required for all 11 – 12 year old students 
entering public schools (barring a medical exemption) how many of the 6 million cases of HPV 
would still occur ten or twenty years down the road [39]? Vaccine efficacy research boasts that 
very few would occur and dramatic reductions in cervical cancer and other HPV-associated 
cancers would also plummet.  
Other ways to increase vaccine compliance falls to physicians or other healthcare 
providers to speak positively about the HPV vaccine. Many parents are not conscientious of all 
the vaccines a child needs and when, but health professionals need to be. Similarly, if someone’s 
pediatrician, pharmacist, or nurse tells a parent that the HPV vaccine is not required and treats it 
as unimportant then that parent will most likely treat it as unimportant as well. The entire health 
community needs to be well educated on the HPV vaccines potential and when it should be 
administered. By emphasizing the HPV vaccines importance, safety, and efficacy all health 
professionals can increase vaccine uptake. 
 Vaccines for Children (VFC) is doing important work by providing free HPV 
vaccinations to children who qualify for the program, but those who do not qualify are forced to 
pay $450 or whatever insurance does not cover for the vaccines. Incentives such as rebates, tax-
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refunds, or insurance discounts for those receiving the vaccine will also raise vaccine 
compliance. The greatest hindrance to vaccine compliance currently is a lack of knowledge of 
HPV, its consequences, and that the HPV vaccine will prevent it up to 99%. Money spent on 
HPV vaccine education would be well spent. Information at doctors’ offices and schools for 
parents to read and learn about the vaccines effectiveness and safety would increase vaccine 
uptake exponentially.  
Global HPV Vaccine Coverage 
HPV remains a global health concern.  However, the United States, Australia, and 
Western Europe are lowest in HPV infection and death from HPV-associated cancers. This is 
because each of these developed countries is currently offering HPV vaccinations to the 
population and encouraging stricter requirements on vaccination [14]. HPV infection and death 
from HPV-associated cancers is highest in developing countries including sub-Saharan Africa, 
Melanesia, Latin America, the Caribbean, south-central Asia, and south-east Asia [17]. To put in 
perspective, 80% of the deaths attributed to HPV worldwide occur in countries such as these. 
These areas do not have access to pharmaceuticals and do not have screening procedures in place 
to catch HPV-associated cancers seen in the US. Without screening measures already in place it 
is actually more cost-effective to initiate preventative vaccinations rather than start screenings 
such as pap smears. There is also little to no treatment available for those who develop HPV-
caused cancers in developing nations.  However, there are many groups advocating that 
vaccinating everyone in the world is a priority and are making a difference in these developing 
nations. Namesake of the 4vHPV vaccine itself, the Gardasil Access Program has shipped 1.3 
million doses of 4vHPV to 21 countries as of July 2016[40].  
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Table 2 Countries Receiving HPV Vaccines Through the Gardasil Access Program [39] 
Honduras Haiti Kiribati Bolivia Mali Ghana Guyana Cameron 
Zambia Moldova Georgia Uganda Kenya Tanzania Lesotho Mongolia 
Nepal Bhutan Cambodia Uzbekistan Papua New Guinea   
As of 2016, the Gardasil Access Program will fully vaccinate (3 doses) more than 
445,900 women who would otherwise be completely unvaccinated [41]. Implementation of these 
kinds is doubly hard because of transportation of medical supplies and product and reaching 
people who are currently out of reach of vaccines. After their initial vaccination it is very 
difficult to make sure the women who received one dose return to receive the subsequent doses 
of the vaccine. PATH, an innovative company who creates vaccines and medical supplies with 
developing countries in mind took on multiple HPV vaccination projects in India between 2008 
and 2011. In India they supplied and vaccinated 52,755 women thereby preventing the spread of 
HPV and the development of cervical cancer[41].  
The largest entity that is advocating immunizations, including HPV vaccination, in 
developing countries is GAVI, the Vaccine Alliance[42]. GAVI is based in Geneva, Switzerland 
and was created in 2000 with the mission to improve access and use of vaccines for children 
living in the poorest countries in the world. Governments of developed countries across the 
world such as the UK, US, Sweden, Norway, Canada, and Australia partner with GAVI to 
increase child immunizations [43]. Currently the United States is in a contract with GAVI to 
provide $1 billion over 4 years (2015 – 2019) [43]. Private funds are also donated and combined 
to fund this vaccine-giving giant. Currently, GAVI is supporting 20 or more projects in various 
countries across Africa and in total approximately 400,000 women are expected to receive life-
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saving HPV vaccination [41]. These companies are saving millions of lives annually by 
providing free and complete HPV vaccinations. 
Conclusion 
In summary, HPV is a very serious infection affecting millions of men and women in 
both developed and developing nations every year. The HPV vaccines that are on the market 
today, 2vHPV, 4vHPV, and 9vHPV, are extremely safe as well as extremely effective at 
preventing HPV. There is strong evidence supporting HPV vaccines effectiveness and duration 
even though they are reasonably new. The largest obstacle facing increased HPV vaccinations is 
a lack of public knowledge and understanding about HPV and HPV vaccines. By educating 
parents formally on HPV statistics such as half of sexually active people will contract HPV at 
some point in their life and that 98% of cervical cancer cases are HPV caused, vaccine uptake 
can be increased [3].  
By educating the public that men are just as at risk for several serious types of cancer 
similar to women more men will seek vaccination for themselves then their sons. Additionally, 
people will be more open to policy to enact restrictions, which make HPV vaccinations required 
for children 11 – 12. All of this knowledge will eventually provide well-protected communities 
for kids to grow and never contract HPV. By never contracting HPV they will never have 
persistent HPV and as a result will never be a part of the currently 270,000 deaths attributed to 
HPV caused cervical cancer alone each year [3]. As HPV vaccine compliance continues to rise 
and the evidence continues to show how it is making a positive difference in countries will 
continue to support groups such as GAVI who are reaching formally unreached people with life-
saving vaccines. HPV is a 99% preventable disease that has not been beaten. Now is the time to 
get vaccinated and educate all people on the importance of the HPV vaccine. [44] 
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